نتائج البحث - "Nodera, H"

1

A homozygous loss-of-function mutation in DNAJA3 causes HMSN type V

المؤلفون: Kawarai, T, Miyamoto, R, Yukiko, K, Omoto, M, Ueyama, M, Murakami, N, Furukawa, T, Osaki, Y, Banzrai, C, Nodera, H, Orlacchio, A, Hashiguchi, A, Higuchi, Y, Takashima, H, Kanda, T, Izumi, Y, Nagai, Y, Mitsui, T, Kaji, R

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______3982::e7e8fbbbd0d97a628e05a0cd4f1277ef
http://hdl.handle.net/11391/1391859

2

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial

المؤلفون: Hanna, M.G., Badrising, U.A., Benveniste, O., Lloyd, T.E., Needham, M., Chinoy, H., Aoki, M., Machado, P.M., Liang, C., Reardon, K.A., Visser, M. de, Ascherman, D.P., Barohn, R.J., Dimachkie, M.M., Miller, J.A.L., Kissel, J.T., Oskarsson, B., Joyce, N.C., Bergh, P. van den, Baets, J., Bleecker, J.L. de, Karam, C., David, W.S., Mirabella, M., Nations, S.P., Jung, H.H., Pegoraro, E., Maggi, L., Rodolico, C., Filosto, M., Shaibani, A.I., Sivakumar, K., Goyal, N.A., Mori-Yoshimura, M., Yamashita, S., Suzuki, N., Katsuno, M., Murata, K., Nodera, H., Romano, C.D., Williams, V.S.L., Vissing, J., Auberson, L.Z., Wu, M., Vera, A. de, Papanicolaou, D.A., Amato, A.A., Nishino, I., RESILIENT Study Grp

المساهمون: Neurology, ANS - Neuroinfection & -inflammation, UCL - SSS/IONS/NEUR - Clinical Neuroscience, UCL - (SLuc) Service de neurologie, RESILIENT Study Grp

المصدر: Lancet neurology, 18(9), 834-844. Lancet Publishing Group
The Lancet. Neurology, Vol. 18, no. 9, p. 834-844 (2019)
The lancet neurology
The Lancet Neurology, 18(9), 834-844
Hanna, M G, Badrising, U A, Benveniste, O, Lloyd, T E, Needham, M, Chinoy, H, Aoki, M, Machado, P M, Liang, C, Reardon, K A, de Visser, M, Ascherman, D P, Barohn, R J, Dimachkie, M M, Miller, J A L, Kissel, J T, Oskarsson, B, Joyce, N C, Van den Bergh, P, Baets, J, De Bleecker, J L, Karam, C, David, W S, Mirabella, M, Nations, S P, Jung, H H, Pegoraro, E, Maggi, L, Rodolico, C, Filosto, M, Shaibani, A I, Sivakumar, K, Goyal, N A, Mori-Yoshimura, M, Yamashita, S, Suzuki, N, Katsuno, M, Murata, K, Nodera, H, Nishino, I, Romano, C D, Williams, V S L, Vissing, J, Auberson, L Z, Wu, M, de Vera, A, Papanicolaou, D A & Amato, A A 2019, ' Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT) : a randomised, double-blind, placebo-controlled phase 2b trial ', The Lancet Neurology, vol. 18, no. 9, pp. 834-844 . https://doi.org/10.1016/S1474-4422(19)30200-5

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, medicine.medical_specialty, Myostatin, Guidelines, Population, Guidelines, Antibodies, Monoclonal, Humanized, Placebo, Myositis, Inclusion Body, law.invention, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Randomized controlled trial, law, Internal medicine, medicine, Humans, education, Adverse effect, Bimagrumab, Aged, Aged, 80 and over, education.field_of_study, business.industry, Repeated measures design, Middle Aged, Myostatin, Settore MED/26 - NEUROLOGIA, Treatment Outcome, 030104 developmental biology, Blood chemistry, Tolerability, Female, Human medicine, Neurology (clinical), business, 030217 neurology & neurosurgery